» Articles » PMID: 19740915

Combined Cyclosporine and Prednisolone Therapy in Adult Patients with the First Relapse of Minimal-change Nephrotic Syndrome

Overview
Date 2009 Sep 11
PMID 19740915
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although minimal-change nephrotic syndrome (MCNS) is highly steroid-responsive, some patients show frequent relapses, necessitating administration of repeated courses of prednisolone (PSL) at high doses. The adverse effects of long-term PSL treatment include osteoporosis, infection, diabetes, cataract, etc., most of which are serious. It is therefore necessary to establish useful strategies to reduce the PSL dose.

Methods: Patients with the first relapse of MCNS were randomly assigned to two groups, namely, the CyA (AUC 1700-2000 ng/ml) + PSL (0.8 mg/kg/day) group (n = 26) and the PSL alone (PSL) (1.0 mg/kg/day) group (n = 26), and the clinical characteristics were compared between the two groups. All patients used C2 for CyA monitoring.

Results: A significant decrease of the urinary protein excretion (P = 0.02) and serum total cholesterol (P = 0.003) was observed at 2 weeks from the first relapse in the CyA + PSL group. The increase in the serum total protein (P = 0.03) and serum albumin (P = 0.007) as compared with that in the PSL group was also observed in the CyA + PSL group at this time-point. The time to remission in the CyA + PSL group was shorter than that in the PSL group (P = 0.006).

Conclusion: It was possible to obtain early remission and reduce the PSL dose with combined CyA and PSL therapy in patients with MCNS.

Citing Articles

Japanese clinical practice patterns of primary nephrotic syndrome 2021: a web-based questionnaire survey of certified nephrologists.

Wada T, Shimizu S, Koizumi M, Sofue T, Nishiwaki H, Sasaki S Clin Exp Nephrol. 2023; 27(9):767-775.

PMID: 37310570 DOI: 10.1007/s10157-023-02366-6.


Steroid Minimization in Adults with Minimal Change Disease.

Koirala A, Jefferson J Glomerular Dis. 2023; 1(4):237-249.

PMID: 36751385 PMC: 9677715. DOI: 10.1159/000517626.


Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.

Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A J Nephrol. 2022; 35(4):1135-1144.

PMID: 35366214 DOI: 10.1007/s40620-022-01279-z.


Interventions for minimal change disease in adults with nephrotic syndrome.

Azukaitis K, Palmer S, Strippoli G, Hodson E Cochrane Database Syst Rev. 2022; 3:CD001537.

PMID: 35230699 PMC: 8887628. DOI: 10.1002/14651858.CD001537.pub5.


Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: a meta-analysis.

Lu J, Xu Z, Xu W, Gong L, Xu M, Tang W Int Urol Nephrol. 2022; 54(9):2205-2213.

PMID: 35102517 PMC: 9372126. DOI: 10.1007/s11255-022-03122-7.